



NOVEL HERBAL FORMULATIONS FOR THE PREVENTION AND MANAGEMENT OF DIABETES AND CARDIOVASCULAR DISORDER

Vinayak Kashid¹, Shyam Wamanrao Rangari², Shaikh Amir Afzal^{3*}, Paramita Ganguly⁴, Amit Kumar Singh⁵, Ankur patel⁶, Rajeev Ranjan⁷, Mayuri Yogesh Baviskar⁸

Article History: Received: 30.05.2023

Revised: 02.07.2023

Accepted: 10.08.2023

Abstract

This present investigation is based on novel herbal formulation for the prevention and management of type-2 diabetes mellitus and cardiovascular disorder associated with diabetes comprising, preparing of ethanolic extract of *Momordica charantia* fruits at 70°-80°C, maintaining P^H of the solution between 7-10, transdermal patches of ethanolic extract of M charantia was prepared. These transdermal patches of extract were used for the prevention and management of diabetes and cardiovascular disorder.

Keywords: Diabetes mellitus; M. charantia Linn; diethyl ether fraction; transdermal patch.

¹Department of Pharmaceutical Quality Assurance, Genesis Institute of Pharmacy, Radhanagari, Opposite to Bharat Petroleum, Kolhapur, Maharashtra. 416212

²Smt. Kishoritai Bhoyar College of Pharmacy Kamptee, Nagpur, Maharashtra, India.

^{3*}Department of Pharmaceutics, SCES's Indira College of Pharmacy, Tathwade, Pune, Maharashtra. 411033

⁴Department of Pharmaceutical Technology, Brainware university, Barasat, Kolkata. 700125

⁵United Institute of Pharmacy, A-31/1 Upside, Industrial Area, Naini, Prayagraj, Uttar Pradesh. 211010

⁶Sardar Patel College of Pharmacy, Vidyanagar-Vadtal Road, Bakrol, Gujarat. 388315

⁷University Department of Chemistry, DSPM University, Morhabadi, Ranchi. 834008

⁸Gahlot Institute of Pharmacy, Kopar Khairane, Navi Mumbai, Thane, Maharashtra. 400709

*Corresponding Author

Shaikh Amir Afzal^{3*}

^{3*}Department of Pharmaceutics, SCES's Indira College of Pharmacy, Tathwade, Pune, Maharashtra. 411033

DOI: 10.31838/ecb/2023.12.s3.835

1. Introduction

Cardiovascular diseases are disease related to heart or blood vessels. The rate of death by CVDs is high globally around 17 million deaths. WHO reported 31% annual deaths globally due to CVDs. The main cause for CVDs is due to genetic, diabetic's obesity, smoking, life style elevated levels of low-density lipoproteins (LDL) and reduced HDL levels.

Diabetes mellitus is a chronic metabolic disorder characterized by increased blood glucose concentration (hyperglycemia) caused by insulin deficiency and it is often combined with insulin resistance. Non-insulin dependent diabetes mellitus (NIDDM) represents a heterogeneous group comprising milder form of diabetes that occurs predominately in adults and vast majority of diabetic patients have NIDDM.[1] The conventional drug treatment of diabetes mellitus consists of oral hypoglycemic agents like sulfonylureas, biguanid's, α -glycosidase inhibitors and thiazolidine diones which have side effects. An important problem in the drug therapy is the lack of patient compliance. Transdermal drug delivery system (TDDS) thus offers a better route of delivery, reported to have better patient compliance.[1] Transdermal drug administration generally refers to topical application of agents to healthy intact skin either for localized treatment of tissues underlying the skin or for systemic therapy. For transdermal products the goal of dosage design is to maximize the flux through the skin into the systemic circulation and simultaneously minimize the retention and metabolism of the drug in the skin.[2] TDDS can deliver certain medication to systemic circulation in a more convenient and effective way than is possible with conventional dosage form. The potential of skin as a path of drug administration has been amply demonstrated by the acceptability of marketed therapeutic systems.[3] TDDS can minimize first-pass metabolism associated with gastro-intestinal administration of drugs. The TDDS can maintain constant drug level in blood. It is possible to enhance the transdermal permeation of drug using penetration enhancers.[4] The present investigation was aimed to formulate transdermal films

incorporating diethyl ether fraction of ethanolic extract of *Momordica charantia* fruits.

Diethyl ether fraction contains mainly charantin, which is a mixture of two compounds, namely, sitosterylglucoside and stigmasterylglucoside. Charantin is used to treat diabetes and can potentially replace treatment by injection of insulin, which has not been successful in stimulating the pancreases of the diabetic patients to lower blood sugar to the desired level.[5] Plant derived compounds that show anti-diabetic property such as charantin and others are now being widely accepted as an alternative medicine for treating diabetes mellitus, and they are free from any side effects. Hence present research is designed to overcome diabetics mellitus associated CVDs.

2. Materials

Ethanolic extract of *M. charantia* fruit was extracted and isolated by successive extraction process. We further carried out the fractionation of extract by using diethyl ether to isolate steroids. Various chemicals are used which includes Hydroxy propyl methyl cellulose K100M (HPMC), Polyethylene glycol (PEG). Alloxan monohydrate. Standard drugs like Glipizide, a anti-diabetic drug was purchased.

Animals

Wistar albino rats of either sex weighing 160-220 g were maintained under standard environmental laboratory conditions and fed with laboratory diet and water *ad libitum*. All the protocols were performed in accordance with the Institutional Animal Ethics Committee (DYPIPSR/ IAEC/10-11/P-02).

Preparation of transdermal patches of *Momordica charantia*

Transdermal patches were prepared by solvent evaporation technique. The polymer (HPMC) and diethyl ether fraction of *M. charantia* were weighed. PEG, which acts as a plasticizer and permeation enhancer, was used in the concentration of 30 % v/v. Ethanol was used as a solvent. PEG 400 (30% weight of polymer) was dissolved in ethanol with stirring, which serve the purpose of plasticizer

as well as penetration enhancer and then calculated amount of HPMC (500 mg) was dispersed in solvent ethanol. Diethyl ether fraction of *M. charantia* (290 mg) was dissolved in ethanol; this solution was then added to polymer base and stirred continuously to get uniform solution. The final volume was made up using water. The above solution was then poured into Petri plate coated with liquid paraffin and then dried at room temperature. After drying, patches were removed and cut into 2 cm² area and wrapped with aluminum foil and kept in desiccators until they were used for further study.[6]

Evaluation parameters of transdermal patches of *M. charantia*

Weight variation test

The weight of each patch was taken using analytical weighing balance (Shimadzu). The mean weight of the film as well as deviation from the mean was obtained and the data was recorded.

Folding endurance

The folding endurance was measured manually for the prepared patches. The patches were repeatedly folded at the same place till it broke. The number of times the patches could be folded at the same place without breaking gives the accurate value of folding endurance.

Thickness

The thickness of patches was determined using digital vernier caliper (Radical Co Mitu-toyo). The mean thickness was measured at five different points of film.

Drug content study

Transdermal patches were taken (2 cm² area) individually, crushed, and taken in a 100-ml volumetric flask (pH 7.4 phosphate buffer). The medium was stirred with a teflon-coated magnetic bed for 2 h. The contents were filtered using Whatmann filter paper and the suitable dilutions of the filtrate were prepared by using phosphate buffer pH 7.4. Absorbance of dilutions were measured by using UV-Vis spectrophotometer (Shimadzu) 1701, at 276.5 nm against phosphate buffer pH 7.4 as a blank.

Drug polymer interaction studies

Drug-polymer interaction was investigated using Fourier Transform Infrared (FTIR). FTIR of diethyl ether fraction of *M. charantia*, polymer (HPMC) and mixture of diethyl ether fraction and polymer were taken using Shimadzu 8400S FTIR spectrophotometer with KBr pellets.[7,8]

In vitro evaluation of transdermal patches

The *in vitro* skin permeation experiments were conducted using Franz diffusion cell (receptor compartment capacity: 20 ml). Full thickness skin from dorsal region of Wistar rat, whose hair had been removed on the previous day with hair removal cream, was used as membrane. The rats were sacrificed by cervical dislocation and the fatty material was removed from dissected skin and skin was washed with phosphate buffer used immediately. The receiver compartment was filled with 20 ml of 10 % hydroalcoholic phosphate buffer, pH 7.4. The transdermal patch was firmly pressed onto the center of the rat skin and then the skin was mounted on the donor compartment. The donor compartment was then placed in position such that the surface of dermis side skin just touches the receptor fluid surface. The whole assembly was kept on a thermostatically controlled magnetic stirrer set at 37 ± 2°C and the content in the receiver compartment was continuously stirred at a constant speed (100 rpm) using a magnetic bead. The samples (2 ml) were withdrawn at the intervals of half hour up to 6 hr. and replaced with same amount (2 ml) of 10% hydroalcoholic phosphate buffer to maintain the sink condition. The samples were analyzed for drug content using UV-Vis spectrophotometer (Shimadzu 1701) at 276.5 nm. The cumulative % drug release from the transdermal patch of *M. charantia* was then calculated by using PCP DISSO software.[1,9]

In vivo evaluation of transdermal patches

Skin irritation study

The rats whose hair were removed on previous day, were divided into three groups (n = 6) and treated as follows. Group I – Normal control group, animals in group II were treated with formalin solution (a standard irritant; 0.8% v/v) upto 7 days, animals in group III were treated with transdermal patches of *M.*

charantia (2 cm², 10 mg/patch) by using USP adhesive tape for 7 days.

The animals were treated daily with formalin solution and new transdermal patches of *M. charantia* upto 7 days by using USP adhesive tape. After 7 days animals were sacrificed and treated skin samples were processed for histological examination.

Antihyperglycemic activity in diabetic rats

Induction of diabetes

Diabetes was induced by of alloxan monohydrate (120 mg/kg, i.p) in saline solution. The diabetic state was confirmed 48 hr after alloxan injection by hyperglycemia. Surviving rats with fasting blood glucose level higher than 250 mg/dl were included in the study.

Acute study

The hairs on the backside of the rat were removed with a hair removal cream on the previous day of the experiment. Following an overnight fast, rats were divided into four groups(n = 6). The rats were treated as following:

Group I (NC) received 0.9% w/v saline (1 ml/kg, p.o.), group II (DC) received 0.9% w/v saline (1ml/kg, p.o.), group III (STD) received Glipizide(5 mg/kg, p.o), group IV (HT) received herbal tablet (89 mg/kg, p.o). Animals in group IV (TEST) were treated with new transdermal patch of *M. charantia* (2 cm²; 10 mg/kg) by using USP adhesive tape [Figure 1].



Fig 1 Application of transdermal patches of extracted *M. Charantia*

At 0 min, 30 min, 1 hr, 2hr, 6 hr, and 24 hr after drug administration and patch application, blood was collected by puncturing tail vein under light ether anesthesia by using fine syringe in epindroff. Plasma glucose levels were estimated by the GOD/POD method

Sub-acute study

The hairs on the backside of the rat were removed with a hair removal cream on the previous day of the experiment. Following an overnight fast, rats were divided into four groups (n = 6). The rats were treated as following:

Group I (NC) received 0.9% w/v saline (1 ml/kg/day, p.o.) for 14 days, group II (DC)

received 0.9% w/v saline (1ml/kg/day, p.o.) for 14 days, group III (STD) received Glipizide (5 mg/kg/day, p.o) for 14 days. Group IV (HT) received herbal tablet (89 mg/kg/day, p.o) for 14 days. Animals in group IV (TEST) were treated daily with new transdermal patch of *M. charantia* (2 cm²; 10 mg/kg) upto 14 days by using USP adhesive tape.

At day 1, day 8, and day 14 after drug administration and patch application, blood was collected by puncturing retro-orbital plexus under light ether anesthesia by using fine glass capillary in epindroff. Plasma glucose levels were estimated by the GOD/POD method. At day 14, blood was collected from animals of all groups and serum

was separated off. TC, TG, HDL-C measured by using enzymatic kit of Bio Lab Diagnostics Pvt. Ltd. Company. According to that result LDL-C, VLDL-C and atherogenic index were calculated.

Biochemical evaluation

At the end of each week of treatment, all the animals were anesthetized with anesthetic ether and blood was withdrawn by puncturing retro-orbital plexus by using fine glass capillary and collected in epindroff tubes and used for estimation of plasma glucose (GOD/POD method). Likewise at the end of 7th and 14th day of treatment blood was withdrawn by puncturing retro-orbital plexus by using fine glass capillary and collected in epindroff tube. The serum was used for estimation of total cholesterol (COD/POD method), triglyceride (GPO/POD method), HDL-C, LDL-C, and VLDL-C.

Statistical analysis

Data are expressed as mean \pm SEM and statistically analyzed by ANOVA followed by Dunnett test.

3. Results

Physicochemical parameters of transdermal patches of *M. charantia*

In the present study, transdermal patches of *M. charantia* were prepared using HPMC K100M. PEG was used as plasticizer as well as penetration enhancer. The films were evaluated for their physical characteristics, such as weight variation, folding endurance, thickness, drug content study, and release characteristics. The physicochemical properties viz. weight variation test, folding endurance, thickness, and drug content of transdermal patches were within the limits [Table 1].

Table 1 Physicochemical properties of transdermal patches of *M. charantia*

Parameters	Transdermal Patches of <i>M. charantia</i>
Weight variation test	0.04 \pm 0.00 gm
Folding endurance	340 \pm 06.89
Thickness	00.06 \pm 0.00 mm
Drug content	97%

From the FTIR spectra, it was clearly evident that there were no interactions of the drug with the polymer. The main peaks in the spectrum of diethyl ether fraction of *M. charantia* do not show any substantial difference when fraction was combined with polymer. Transdermal patches of *M. charantia* (2 cm² area; 10

mg/patch) showed good release characteristics in hydroalcoholic phosphate buffer medium than in phosphate buffer solution. *In vitro* release profile of transdermal patches of *M. charantia* (2 cm²; 10 mg/patch) showed 47.59% drug release in six hours [Figure 2].




Figure 2: Cumulative % drug release transdermal patches of M.Charantia

Skin irritation test

The histopathological examination of the skin indicates that prepared systems produced mild inflammation. Formalin produced high grade of irritation, indicated by severe inflammation.

Group treated with Glipizide showed significant decrease in plasma glucose level at 1 hr, 2 hr, and 6 hr when compared with diabetic control group. Group treated with HT, TEST group showed significant decrease ($P < 0.01$) in plasma glucose level at 2 hr and 6 hr when compared with diabetic control group [Table 2].

Anti-hyperglycemic activity in diabetic rats

Acute study

Table 2 Effect of transdermal patches on plasma glucose level in diabetic rats (acute study)

Group	Plasma glucose level (mg/dL)		
	Day 1	Day 8	Day 14
NC	78.8±0.03	80.2±1.93	77.2±1.96
DC	285±01.96	290±01.33 ^{##}	283±01.69 ^{##}
STD	285±02.05	222±04.84 ^{**}	160±02.75 ^{**}
HT	285±2.08	240±13.97 ^{**}	209±1.90 ^{**}
TEST	287±1.46	277±1.45 ^{**}	251±1.38 ^{**}

Sub-acute study

The transdermal patches produced significant decrease in blood glucose levels upto 14 days indicating that these devices provide optimum Anti-hyperglycemic effects upon long-term application also. Groups treated with Glipizide showed significant decrease ($P < 0.01$) in plasma glucose level on day 8 and onwards, this significant anti-diabetic activity remains also at the end of treatment schedule (on day 14). Also groups treated with HT, TEST showed significant decrease ($P < 0.01$) in plasma glucose level at the end of treatment schedule (on day 14) [Table 3].

Table 3 Effect of transdermal patches on plasma glucose level in diabetic rats (subacute study)

Group	Plasma glucose level (mg/dL)		
	Day 1	Day 8	Day 14
NC	77.58±2.10	79.2±1.95	77.4±1.97
DC	286±01.99	292±01.36 ^{##}	283±01.70 ^{##}
STD	286±02.06	220±04.85 ^{**}	160±02.76 ^{**}
HT	286±2.07	239±13.98 ^{**}	210±1.91 ^{**}
TEST	285±1.41	273±1.42 ^{**}	252±1.32 ^{**}

4. Discussion

In present study, transdermal patches of *M. charantia* (2 cm²; 10 mg/kg), produced a significant reduction in blood glucose of diabetic rats, hence the transdermal patches of *M. charantia* have anti-hyperglycemic activity. The blood glucose lowering effects of transdermal patches of *M. charantia* in diabetic rats was higher at 6 hr. Its preparations are reported to increase glucose utilization by liver and increase cellular uptake of glucose, promote, insulin release and potentiate its effect, which is probably responsible for the anti-diabetic effect. The other species of this genus, *Momordica cymbalaria* have been reported to have anti-hyperglycemic activity.[10] A variety of orally active hypoglycemic agents are frequently used to help to manage the glucose intolerance of NIDDM patients. But the effectiveness of these drugs is limited and suffers from a variety of side effects including hypoglycemia.[11] Many patients develop failure to oral anti-hyperglycemic agents. All these factors together reduce compliance. On the other hand, plant extracts evaluated in this study are commonly used vegetable in India and juice of fruits of this plant is commonly employed as a household remedy for diabetes.

5. Conclusion

In the present research work an ethanolic extraction *M. charantia* were done by successive extraction process. Transdermal patches *M. charantia* were prepared, the prepared transdermal patches was evaluated for various parameters and parameters holds good. This herbal extracted transdermal patches were screened for anti-diabetic activity shown promising activity. Hence it is

concluded that the novel herbal formulation of *M. charantia* shown potent activity in prevention and management of diabetes mellitus and cardiovascular disorder respectively.

6. References

- Mutalik S, Udapa N, Kumar S, Agarwal S, Subramanian G, Ranjith AK. Glipizide matrix transdermal systems for diabetes mellitus: Preparation, *in vitro* and preclinical studies. *Life Sci.* 2006;79:1568–77.
- Mishra AN. Controlled and novel drug delivery. In: Jain NK, editor. *Transdermal Drug Delivery*. New Delhi: CBS Publishers; 1997. pp. 100–101.
- Bhalla HL, Bhate AS. Feasibility studies on transdermal films of ephedrine. *Indian Drugs.* 1994;31:328–32.
- Lalla JK, Seethalakshmi KR, Dattani KK. Nitroglycerin controlled release transdermal patch. *Indian Drugs.* 1988;26:284–95.
- Sook YL, Seok HE, Young KK, Nam P, Sang UP. Cucurbitane-type triterpenoids in *Momordica charantia* Linn. *J Med Plants Res.* 2009;3:1264–9.
- Das A, Ghosh S, Dey B, Das S. A novel technique for treating the type-II diabetes by transdermal patches prepared by using multiple polymer complexes. *Int J Pharm Res Develop - Online.* 2010;2:195–204.
- Das K, Dang R, Bhaskaran S, Roopashree TS. Recent advances in Medicinal Plants in Diabetes Treatment. Recent Progress in Medicinal Plants. *Phytopharmacology and Therapeutic values I (14)* 2008;19:150–91.
- Ahad HA, Chitta SK, Anil KB, Amarnath RB, Chandrashekar AV, Gangadhar

- Permeation studies of Diclofenac sodium from Ficus carica fruit mucilage matrices for transdermal delivery. *Int J Pharm Tech Res.* 2010;2:1013–7.
9. Heard CM, Johnson S, Moss G, Thomas CP. *In vitro* transdermal delivery of caffeine, theobromine, theophylline and catechin from extract of Guarana, *Paullinia cupana*. *Int J Pharm.* 2006;317:26–31.
 10. Rao BK, Kesavulu MM, Apparao Ch. Antihyperglycemic activity of *Momordica cymbalaria* in alloxan diabetic rats. *J Ethnopharmacol.* 2001;78:67–71.
 11. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of endocrine pancreas. In: Hardman JG, Limbird LE, editors. *Goodman and Gilman's. The pharmacological basis of Therapeutics.* 9th edition. New York: McGraw-Hill; 1996. p. 1503.